US EditionPublished • loading... • Updated
‘Life-changing’ asthma drug only requires two jabs a year
Depemokimab, given twice yearly, reduces hospital admissions by 72% for severe asthma patients and eases NHS pressures, according to trial results.
- This month the MHRA authorised depemokimab, GSK's biologic to be sold as Exdensur, and plans to begin UK sales within months.
- GSK scientists in Stevenage, Hertfordshire made two structural tweaks so the antibody can last six months without extra side-effects, aiding patients whose inhalers are insufficient.
- A trial of 762 patients showed depemokimab cut hospital admissions by 72 per cent with minimal side-effects, while patients previously relied on high-dose steroids causing mood changes, weight gain, high blood sugar and osteoporosis.
- Kaivan Khavandi said the twice-yearly schedule will reduce clinic visits and free NHS resources, while David Jackson warned patient access depends on the company's forthcoming price announcement in the coming weeks.
- About six million people in England have asthma, with roughly 58,000 adults eligible for biologics and about 21,000 currently receiving them; Exdensur is due privately in the first half of 2026 and NICE will decide next year.
Insights by Ground AI
4 Articles
4 Articles
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year – UK Times
Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available in Britain. The pharmaceutical giant GSK has been granted marketing authorisation Medicines and Healthcare Products Regulatory Agency (MHRA) for depemokimab. The treat…
Coverage Details
Total News Sources4
Leaning Left2Leaning Right0Center1Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
C 33%
Factuality
To view factuality data please Upgrade to Premium
